Skip to content

The research on menopause syndrome--The clinical research of Bushenjiangzhi formula on menoapuse dyslipidemia

The research on menopause syndrome--The clinical research of Bushenjiangzhi formula on menoapuse dyslipidemia

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-16007697
Enrollment
Unknown
Registered
2016-01-04
Start date
2016-02-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

menopause related disease

Interventions

treatment group:herbs
control group:Placebo

Sponsors

Guangdong Provincal hospital of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
41 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Women aged 41-60 years; 2. Meet the diagnosis of dyslipidemia;and is primary hyperlipidemia; 3. The level of blood lipid should be TC 5.18mmol/L to 6.19mmol/L; LDL-C 3.37 mnol/L to 4.12mmol/L; TG1.70mnol/L to 2.25mmol/L; 4. 10 year cardiovascular risk<10% (with QRISK2Risk assessment calculator); 5. Meet the diagnosis criteria of TCM syndrome of Liver and kidney Yin deficiency syndrom; 6. Kupperman index (KI)<15; 7. Did not use any of the following treatment for at least 4 weeks before entry into the study: Other Drugs Effect of blood lipid reduction, hormone therapy, selective elective estrogen receptor modulators, aromatase inhibitors, soybean extracts or Chinese medicine; 8. Be able and voluntary to sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with secondary dyslipidemia and with familial hypercholesterolemia; 2. High risk factor of coronary heart disease, such as unstable angina, acute myocardial infarction, postoperative of coronary stent implantation or postoperative of coronary artery bypass grafting; 3. the risk of 10 year cardiovasular heart disease >=10%(with QRISK2 risk assessment calculator); 4. Over 10 years of I types of diabetes,and with kidney disease or other cardiovascular disease risk factors; 5. Patients with carotid artery stenosis, transient ischemic attack, stroke and peripheral vascular disease patients; 6. Severe liver or/and renal insufficiency;hematopoietic system disease or malignant tumor; 7. Patients with mental illness (schizophrenia, bipolar disorder, paranoid psychosis or paitents obvious suicidal depression); 8. Alcohol consumption; 9. Participate in the I, II period clinical trial within the last 6 months or III, IV period clinical trial within the last 3 months; 10. Allergic to trial medication or f patients with allergic constitution; 11. Patients with muscle or joint diseases which hinder the paitents do moderate intensity exercis(such as osteoarthritis, rheumatoid arthritis, synovitis and so on).

Design outcomes

Primary

MeasureTime frame
blood lipids;

Secondary

MeasureTime frame
Body mass index, waist to hip ratio, blood pressure, ankle brachial index, and skin fold thickness;Blood glucose, insulin, high sensitive C-reactive protein (hs CRP), homocysteine, adiponectin, leptin, endothelial, vascular endothelial growth factor;Carotid artery ultrasonography (carotid artery thickness);

Countries

Chine

Contacts

Public ContactXiaoyun Wang
jiaoshouw@163.com+86 18922108066

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026